Hochuen Medical Technology is a CDMO focused on in vitro diagnostics (IVD), microfluidic biochips, and high-end medical devices. The company develops and manufactures microfluidic chips for point-of-care testing and related medical applications. Management says proceeds from the recent fundraise will be used to expand its CDMO business, develop new technologies, and increase overseas production capacity. Leadership cites strong demand driven by COVID-19 for point-of-care molecular diagnostics and home health tests. Investors and company executives believe microfluidics technology has huge growth potential and expect dramatic changes in the biomedical industry in coming years. Founded in 2016 and headquartered in Shenzhen, Hochuen positions itself for scale-up of chip mass production. Hochuen Medical develops and produces microfluidic and in vitro diagnostic (IVD) devices and consumables, including microfluidic cartridges, POCT devices, gene sequencing chips, and research disposables. The company serves more than 200 customers, including the world’s largest IVD companies and DNA microarray and gene sequencing firms. Hochuen supports customers from R&D through low- and high-volume CDMO manufacturing on microfluidic chips and biomedical consumables. It operates four manufacturing sites in China and Malaysia with tens of thousands of square meters of facilities, including clean rooms and GMP rooms, and maintains sales offices in the United States and Singapore. Founded in 2015 by Dr. Robin Liu and Eric Zeng, the company combines expertise in IVD, microfluidics, and electronics OEM. Future plans described in the articles include international and domestic expansion, development of new manufacturing processes and technologies, and further production capacity growth.

Total raised

$8M

Funding rounds

2

Latest round

Series B

Latest activity

Nov 2022